flow trial semaglutide kidney outcomes hazard ratio 0.76 nejm 2024 Ozempic® (semaglutide injection) Get With the FLOW! in:

7 of 12 patients receiving intra-articular BPC-157 injections for knee pain reported relief lasting more than 6 months

Final Thoughts Switching from semaglutide to tirzepatide is one of the more common transitions in GLP-1 therapyand for some people, its a logical next step when progress stalls or goals shift

The drug is FDA-approved for obesity, weight loss, and chronic weight management but is not a diabetes medication, even though it can help lower blood sugar levels and improve A1c

The right dosage depends on your goals, body type, and how your system responds

The dosing regimen often starts with a lower dose to allow the body to adjust, reducing the likelihood of side effects such as nausea